Status | Study |
Recruiting |
Study Name: Study of ARQ 092 in Patients With Overgrowth Diseases and Vascular Anomalies Condition: Proteus Syndrome PIK3CA-Related Overgrowth Spectrum (PROS) Date: 2017-03-17 Interventions: Drug: ARQ 092 Subjects will receive ARQ 092 orally at the dose level and administration schedule specifi |
Enrolling by invitation |
Study Name: Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome Condition: Proteus Syndrome Date: 2015-10-31 Interventions: Drug: ARQ 092 |
Completed |
Study Name: Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants Condition: Coronary Artery Disease Proteus Syndrome Date: 2011-06-08 |
Recruiting |
Study Name: Study of Proteus Syndrome and Related Congenital Disorders Condition: Growth Disorder Mental Retardation Multiple Abnormalies Date: 1999-11-03 |